Most pharma teams don’t lose the patent race because they don’t care about IP.
They lose because they’re looking in the wrong place—at the wrong time—with the wrong questions.
That’s the uncomfortable truth behind the “intelligence gap” highlighted in …

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400B Biologics War
The biologics market is no longer just a science story—it’s a legal and regulatory chess match worth hundreds of billions of dollars. And at the center o…

Most companies don’t lose because they can’t innovate. They lose because they’re late.
In pharma, timing is everything. A single “expired” or “about-to-expire” patent can turn a protected revenue stream into a competitive free-for-all—overnight. And ye…

AI is becoming the new “KOL”—and if you’re not tracking it, you’re already behind.
For years, pharma has mapped influence the old-fashioned way: key opinion leaders, conference circuits, advisory boards, and the quiet gravity of who gets cited in slide…

Most companies wait until a patent is already dying. The smarter ones start hunting value months—sometimes years—earlier.
If you work in pharma BD, licensing, strategy, or competitive intelligence, you’ve probably seen the pattern: a blockbuster’s excl…

Drug patent expiry isn’t a calendar event—it’s a portfolio risk model.
Most teams treat patent expiry like a deadline: mark the date, track the filing, move on. But in pharma, “the date” is rarely one date. It’s a stack of country-by-country realitie…

Generic entry is inevitable—unless you build a moat that can’t be copied.
Most investors and operators obsess over the obvious: composition-of-matter patents, branded label exclusivity, and blockbuster timelines. But in the real world, generics don’t…